Abstract Library

#3726 Inflammation based index and tumor heterogeneity on pretherapeutic 68Ga DOTATOC PET/CT predict outcome in midgut neuroendocrine tumor patients treated with 177Lu-oxodotreotide

Introduction: Peptide receptor radionuclide therapy with 177Lu oxodotreotide (LuPRRT) is a standard treatment for the management of patients with inoperable metastatic well-differentiated neuroendocrine tumors of the midgut (iNET). As LuPRRT becomes widely used for a heterogeneous population of NET patients, practical predictive biomarkers are needed. Inflammation based index (IBI) derived from serum C reactive protein and albumin is associated with progression free survival (PFS) and overall survival (OS) in patients with PRRT for NETs. Ga-68 DOTATOC PET/CT (DOTAPET) assessment of lesion heterogeneity was predictive for response to PRRT.

Conference:

Presenting Author: Vija L

Authors: Vija L, Dierickx L, Kanoun S, Texier J, Terroir M,

Keywords: LuPRRT, GaDOTA PET/CT, neuroendocrine tumor, outcome,

#3270 Exploration of Ga-68 DOTA PET radiomics to predict the absorbed dose of Lu-177 DOTATATE® therapy of midgut neuroendocrine tumors

Introduction: Lu-177 DOTATATE® is a proficient systemic irradiation with heterogeneous individual consequences due to tumor burden, uptake and elimination. Current dosimetry protocols seem not accurate enough to predict efficacy or toxicity.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Courbon F

Authors: Brahmi S, Vallot D, Vija L, Dierickx L, Courbon F,

Keywords: midgut NET, Ga DOTA PET CT, LuPRRT, PET metrics, SUV, tumor absorbed dose,

#3262 Real-world effectiveness and serotonin reduction in patients with progressive neuroendocrine tumors and carcinoid syndrome receiving telotristat ethyl

Introduction: Clinical trials have demonstrated the efficacy and safety of telotristat ethyl (TE) treatment in combination with somatostatin analogues (SSAs) in patients with neuroendocrine tumors (NETs) and inadequately controlled carcinoid syndrome (CS) diarrhea. The TELEACE study was designed to evaluate the real-world effectiveness of TE in US clinical practice.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Liu E

Authors: Liu E, Giacalone S, Joish V, Dharba S, Yarkoni T,

Keywords: neuroendocrine tumor, carcinoid syndrome, telotristat ethyl, serotonin,

#2750 Progression-Free Survival and Clinical Outcomes with Long-Term Use of Telotristat Ethyl in US Clinical Practice

Introduction: Treatment of advanced neuroendocrine tumors aims to relieve symptoms and suppress tumor growth. Primary findings from the TELEACE study suggested telotristat ethyl (TE) may reduce tumor size and impact tumor growth.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Metz D

Authors: Metz D, Liu E, Joish V, Huynh L, Cheng M,

Keywords: neuroendocrine tumor, carcinoid syndrome, telotristat ethyl, serotonin, tumor growth, progression-free survival,

#380 Diagnosis and Management of Insulinomas in a Tertiary Referral Center: A 10-Year Review

Introduction: Insulinomas are rare tumors. There are few reports of insulinoma from India. We present a retrospective analysis of patients with insulinoma evaluated at a tertiary referral center in South India.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Ramachandran V, Undemane Shivashankara V, Rao G,

Keywords: insulinoma, neuroendocrine tumor, pancreas,